X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ASTRAZENECA PHARMA Fact Sheet, ASTRAZENECA PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA Fact Sheet   (AIDL)

Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ASTRAZENECA PHARMA Price History

Price Rs 958.4
Mkt Cap Rs m 23,960
Vol '000 1.2
P/E X 98.0
P/CF X 249.3
EPS (TTM) Rs 9.8
% ch % -0.8
No. of shares m 25.00
% ch week % 0.5
% ch 1-mth % 4.5
% ch 12-mth % -7.6
52 week H/L Rs 1,147.0/905.0
(As on Jul 26, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ASTRAZENECA PHARMA Financials

No. of Mths
Year Ending
12
Dec-09
15
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
ASTRAZENECA PHARMA EQUITY SHARE DATA
High Rs1,1091,4482,4892,6491,285 
Low Rs4218021,162595634 
Sales per share (Unadj.) Rs158.7237.7212.6156.2189.6 
Earnings per share (Unadj.) Rs23.025.77.9-35.8-0.2 
Diluted earnings per shareRs23.025.77.9-35.8-0.2 
Cash flow per share (Unadj.) Rs25.529.210.8-30.93.8 
Dividends per share (Unadj.) Rs10.0010.003.5000 
Adj. dividends per shareRs10.0010.003.500.000.00 
Dividend yield (eoy) %1.30.90.200 
Book value per share (Unadj.) Rs57.871.975.739.968.6 
Adj. book value per shareRs57.871.975.739.968.6 
Shares outstanding (eoy) m25.0025.0025.0025.0025.00 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x4.84.78.610.45.1 
Avg P/E ratio x33.243.9230.8-45.3-4,712.7 
P/CF ratio (eoy) x30.038.6168.3-52.5249.6 
Price / Book Value ratio x13.215.724.140.714.0 
Dividend payout %43.439.044.300 
Avg Mkt Cap Rs m19,12528,12545,63840,55023,988 
No. of employees `0001.51.71.71.61.6 
Total wages/salary Rs m8281,5051,6191,4851,605 
Avg. sales/employee Rs Th2,710.53,485.63,175.12,458.63,040.2 
Avg. wages/employee Rs Th565.8882.7967.2934.91,029.2 
Avg. net profit/employee Rs Th393.5376.1118.1-563.8-3.3 
ASTRAZENECA PHARMA INCOME DATA
Net Sales Rs m3,9685,9435,3153,9044,740 
Other income Rs m56606310592 
Total revenues Rs m4,0246,0035,3794,0094,832 
Gross profit Rs m8911,038303-685-130 
Depreciation Rs m618873123101 
Interest Rs m10000 
Profit before tax Rs m8841,010293-703-139 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000139 
Tax Rs m308368951935 
Profit after tax Rs m576641198-895-5 
Gross profit margin %22.417.55.7-17.5-2.7 
Effective tax rate %34.836.532.4-27.4-3.7 
Net profit margin %14.510.83.7-22.9-0.1 
ASTRAZENECA PHARMA BALANCE SHEET DATA
Current assets Rs m2,0062,1961,9461,6482,726 
Current liabilities Rs m8941,2541,5512,0592,435 
Net working cap to sales %28.015.87.4-10.56.1 
Current ratio x2.21.81.30.81.1 
Inventory Days Days3235528074 
Debtors Days Days6327222641 
Net fixed assets Rs m3035149029821,035 
Share capital Rs m5050505050 
"Free" reserves Rs m1,3951,7471,843948942 
Net worth Rs m1,4451,7971,8939981,716 
Long term debt Rs m00000 
Total assets Rs m2,3393,0873,4493,0614,156 
Interest coverage x632.4NMNMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x1.71.91.51.31.1 
Return on assets %24.720.85.7-29.2-0.1 
Return on equity %39.935.710.4-89.8-0.3 
Return on capital %61.356.215.5-70.40 
Exports to sales %4.46.86.43.85.7 
Imports to sales %5.36.37.37.16.5 
Exports (fob) Rs m176404343147270 
Imports (cif) Rs m211372388278306 
Fx inflow Rs m287474490296375 
Fx outflow Rs m568613647406470 
Net fx Rs m-282-139-157-111-96 
ASTRAZENECA PHARMA CASH FLOW
From Operations Rs m 326 645 387 -60 -8 
From Investments Rs m 22 -277 -337 -156 -146 
From Financial Activity Rs m -1,109 -291 -291 -103 862 
Net Cashflow Rs m -761 77 -240 -320 709 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

ASTRAZENECA PHARMA Raw Materials Data

ITEM Rs m % To R.M.C. % To SALES
Codeine phosphate 47.7 7.6 1.0
Others 469.6 74.8 9.7
Packaging materials 110.4 17.6 2.3

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 0.3%
FIIs 15.7%
ADR/GDR 0.0%
Free float 9.1%
Shareholders 12,856
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024
E-MAIL comp.secy@astrazeneca.com WEB www.astrazenecaindia.com
TELEPHONE (080) 6774 8000 FAX (080) 2362 2015
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Integrated Enterp., Ramana Residency, 4th Cross, Malleswaram, Bangalore-03
AUDITOR BSR & Co.
CHM: D. E. Udwadia COMP SEC: Anantha Murthy YEAR OF INC: 1900 BSE CODE: 506820 FV (Rs): 2 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   WYETH LTD  TTK HEALTHCARE  PANACEA BIOTECH  ALKEM LABORATORIES  TORRENT PHARMA  

Compare ASTRAZENECA PHARMA With:   WYETH LTD  TTK HEALTHCARE  PANACEA BIOTECH  ALKEM LABORATORIES  TORRENT PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Bull Run in Indian Stock Markets, National Fertilisers OFS, and Top Cues in Action Today(Pre-Open)

Share markets in India closed at their life-time highs yesterday, with Nifty50 settling above the 10,000-mark for the first time. At the closing bell, the BSE Sensex closed higher by 154 points.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Why Keeping Unrealistic Expectations From Investments Is Stupid!(Outside View)

Jul 18, 2017

When investing, keeping realistic returns is necessary and it is not the only thing you should look at.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - ACTAVIS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS